GSK215

Research use only, not for human use.

GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader (pDC50= 8.4), designed using the FAK inhibitor VS-4718 and a binder for the VHL E3 ligase, capable of inducing rapid and prolonged FAK degradation.

GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader with a pDC50 of 8.4. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. GSK215 induces rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels and a marked pharmacokinetic/pharmacodynamics (PK/PD) disconnect.

Western Blot Analysis Cell Line:A549 cells Concentration:0.1-1000 nM Incubation Time:2 h Result:Increased the FAK degradation.Cell Migration Assay Cell Line:A549 cells Concentration:100 nM Incubation Time:48 h Result:Inhibited cell migration.Cell Invasion Assay Cell Line:A549 cells Concentration:100 nM Incubation Time:48 h Result:Inhibited cell invasion.

Animal Model:Male CD1 mice (P878/881A), 7-9 weeks Dosage:8 mg/kg Administration:Single subcutaneous injection Result:Caused a rapid and profound degradation of FAK in liver over time, with a maximal degradation of ~85% being achieved within 18 h. Endogenous FAK was found to still be reduced by ~60% at 96 h post-dose.The Cmax and tmax were 526 ng/mL and 0.33 hours, respectively.

——

Angiogenesis

FAK

FAK | PROTACs

——

——

2743427-26-9

985.13

C50H59F3N10O6S

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (253.77 mM; Ultrasonic )

CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCN(CC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@@H](C)c3ccc(cc3)-c3scnc3C)C(C)(C)C)CC2)ncc1C(F)(F)F

——

(-20℃)

With Ice Pack

≥ 2 years